We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+42.04%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.01B
AUM Growth
+$128M
Cap. Flow
-$241M
Cap. Flow %
-12%
Top 10 Hldgs %
57.08%
Holding
77
New
4
Increased
7
Reduced
4
Closed
25

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$34.9M
2
GPCR icon
Structure Therapeutics
GPCR
+$22.9M
3
ARVN icon
Arvinas
ARVN
+$14.2M
4
TNGX icon
Tango Therapeutics
TNGX
+$9.33M
5
IMVT icon
Immunovant
IMVT
+$9.2M

Top Sells

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$38.2M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$36.5M
3
VTYX
Ventyx Biosciences
VTYX
+$29.5M
4
FOLD
Amicus Therapeutics
FOLD
+$28.3M
5
EXEL icon
Exelixis
EXEL
+$25.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB.WS
51
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$16K ﹤0.01%
266,666
– –
SRZNW icon
52
Surrozen Inc Warrant
SRZNW
$69.7K
$1.33K ﹤0.01%
66,666
– –
ABOS icon
53
Acumen Pharmaceuticals
ABOS
$155M
– –
-2,206,983
Closed -$9.16M
AMLX icon
54
Amylyx Pharmaceuticals
AMLX
$2.26B
– –
-2,084,000
Closed -$38.2M
ASND icon
55
Ascendis Pharma A/S
ASND
$16B
– –
-95,000
Closed -$8.9M
CGEM icon
56
Cullinan Oncology
CGEM
$1.01B
– –
-1,074,082
Closed -$9.72M
CNTA
57
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-770,708
Closed -$4.99M
COGT icon
58
Cogent Biosciences
COGT
$6.65B
– –
-525,000
Closed -$5.12M
EXEL icon
59
Exelixis
EXEL
$13.3B
– –
-1,150,000
Closed -$25.1M
FOLD
60
DELISTED
Amicus Therapeutics
FOLD
– –
-2,325,000
Closed -$28.3M
GOSS icon
61
Gossamer Bio
GOSS
$82.9M
– –
-6,497,700
Closed -$5.41M
MDGL icon
62
Madrigal Pharmaceuticals
MDGL
$10.8B
– –
-100,000
Closed -$14.6M
MRSN
63
DELISTED
Mersana Therapeutics
MRSN
– –
-80,000
Closed -$2.54M
NRIX icon
64
Nurix Therapeutics
NRIX
$2.41B
– –
-1,224,892
Closed -$9.63M
PMVP icon
65
PMV Pharmaceuticals
PMVP
$59.2M
– –
-3,163,795
Closed -$19.4M
RAPT
66
DELISTED
RAPT Therapeutics
RAPT
– –
-37,500
Closed -$4.99M
SAGE
67
DELISTED
Sage Therapeutics
SAGE
– –
-1,094,000
Closed -$22.5M
TCRT icon
68
Alaunos Therapeutics
TCRT
$4.59M
– –
-7,333
Closed -$145K
TSVT
69
DELISTED
2seventy bio
TSVT
– –
-459,836
Closed -$1.8M
VKTX icon
70
Viking Therapeutics
VKTX
$3.7B
– –
-2,000,000
Closed -$22.1M
VRCA icon
71
Verrica Pharmaceuticals
VRCA
$89.7M
– –
-16,696
Closed -$649K
VTYX
72
DELISTED
Ventyx Biosciences
VTYX
– –
-850,000
Closed -$29.5M
XBI icon
73
State Street SPDR S&P Biotech ETF
XBI
$9.95B
– –
-500,000
Closed -$36.5M
NGM
74
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-500,000
Closed -$535K
THRX
75
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
– –
-150,000
Closed -$404K
1 2
3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Boxer Capital held 77 positions worth $2.01B, up 6.8% from $1.88B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Boxer Capital withdrew a net $241M in Q4 2023, closing 25 positions and reducing 4 holdings. Its most notable exit was Amylyx Pharmaceuticals, an estimated $38.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

Against the trend, Boxer Capital opened a new position in Structure Therapeutics worth $16.3M.

  • Boxer Capital's largest Q4 2023 buy was Structure Therapeutics: 400,000 shares worth $16.3M.
  • Boxer Capital added most to argenx in Q4 2023, an estimated $34.9M increase.
  • Boxer Capital's biggest Q4 2023 reduction was Iovance Biotherapeutics, cutting an estimated $12.1M.
  • Boxer Capital fully exited Amylyx Pharmaceuticals in Q4 2023, selling an estimated $38.2M.
  • Boxer Capital's ten largest holdings make up 57% of its $2.01B portfolio in Q4 2023.
  • Boxer Capital opened 4 new positions and closed 25 in Q4 2023.
  • Boxer Capital's portfolio value rose 6.8% quarter-over-quarter to $2.01B.

Based on Boxer Capital's 13F filing for Q4 2023, filed 14 Feb 2024.